drugset / Trial / NCT06707259
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
NaSingle-groupOpen-labelTreatment
Summary
To study the safety and effectiveness of cord blood-derived IL-10/IL-15 CD19-CAR NK in patients with B-cell non-Hodgkin's lymphoma
Timeline
- Start
- 2024-12-01
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 IL10/IL15 CAR-NK | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | anti-CD19 IL10/IL15 CAR-NK | Cell therapy | 4e+06 cells/kg | Intravenous |
| Subject | anti-CD19 IL10/IL15 CAR-NK | Cell therapy | 8e+06 cells/kg | Intravenous |